Lv6
2970 积分 2024-06-26 加入
Durvalumab combined with chemotherapy and Stereotactic Ablative Body Radiotherapy (SABR) in patients with oligometastatic non-small cell lung cancer: a multi-center phase 2 study
13天前
已完结
Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study
13天前
已完结
Contemporary radiotherapy: present and future
17天前
已完结
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
17天前
已完结
Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade
28天前
已完结
Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer
28天前
已完结
High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial
29天前
已完结
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
29天前
已完结
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
29天前
已完结
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint
1个月前
已完结
皖公网安备34019202002308
